CS-2408

生物活性靶点体外研究体内研究 CS-2408 试剂级价格

CS-2408

CAS号:148081-72-5
英文名:1-O-Hexyl-2,3,5-trimethylhydroquinone
中文名:CS-2408
CBNumber:CB61175507
分子式:C15H24O2
分子量:236.35
MOL File:148081-72-5.mol

CS-2408化学性质

熔点 :72.5-73°C
沸点 :357.8±37.0 °C(Predicted)
密度 :0.971±0.06 g/cm3(Predicted)
储存条件 :Inert atmosphere,2-8°C
溶解度 :Chloroform：soluble
形态 :powder to crystal
酸度系数(pKa) :11.22±0.30(Predicted)
颜色 :White to Light yellow to Dark green
LogP :5.255 (est)

安全信息

海关编码 :2909.50.5000

CS-2408性质、用途与生产工艺

生物活性 HTHQ (1-O-hexyl-2,3,5-trimethylhydroquinone) 是一种强力的亲脂性酚类抗氧化剂。HTHQ 通过与活性氧 (ROS) 直接反应并清除 ROS 以形成更稳定的自由基而具有很强的抗氧化活性。
靶点

ROS

体外研究

HTHQ (0-100 μM; 24 hours; PC12 cells) treatment increases cell viabilities in a dose-dependent manner.
HTHQ (10 μM; 0.6-24 hours; PC12 cells) inhibits 3,4-L-Dihydroxyphenylalanine (L-DOPA) -induced phosphorylation of sustaines extracellular signal-regulated kinases (ERK1/2), p38 mitogen-activated protein kinase (MAPK), and c-Jun N-terminal kinase (JNK1/2). HTHQ also normalizes L-DOPA-reduced Bcl-2-associated death protein (Bad) phosphorylation and Bcl-2-associated X protein (Bax) expression, promoting cell survival.

Cell Viability Assay

Cell Line:	PC12 cells
Concentration:	0 μM, 1 μM, 10 μM, and 100 μM
Incubation Time:	24 hours
Result:	Reduced cell viability at 24 hours caused by both 100 and 200 µM L-DOPA was significantly attenuated.

Western Blot Analysis

Cell Line:	PC12 cells
Concentration:	10 μM
Incubation Time:	0.6-24 hours
Result:	Inhibited L-DOPA-induced phosphorylation of sustained extracellular signal-regulated kinases (ERK1/2), p38 mitogen-activated protein kinase (MAPK), and c-Jun N-terminal kinase (JNK1/2). And also normalized L-DOPA-reduced Bcl-2-associated death protein (Bad) phosphorylation and Bcl-2-associated X protein (Bax) expression.

体内研究

HTHQ (50-200 mg/kg; oral administration; for 4 weeks; specific pathogen-free male Sprague Dawley rats) treatment significantly improves liver weight and serum chemistry level. HTHQ reduces hydroxyproline and malondialdehyde level in the liver. HTHQ treatment also reduces fibrotic septa. HTHQ administration shows reduced mRNA level of PDGF (Plateletderived growth factor) , α-SMA (α-smooth muscle actin) and TGF-β (transforming growth factor-β) than DMN-induced hepetic fibrosis animals in the liver tissue.

Animal Model:	48 specific pathogen-free male Sprague Dawley (SD) rats (6-week-old ) with dimethylnitrosamine (DMN)
Dosage:	50 mg/kg, 100 mg/kg, 200 mg/kg
Administration:	Oral administration; for 4 weeks
Result:	Improved against DMN-induced liver fibrosis in male SD rats.